M&A / Property Routine +

Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical

Aptose Biosciences Closes $6.1M Hanmi Takeover, Delisting TSX as Clinical-Stage AML Biotech Exits Public Markets

By The Northwire Desk — AI Analysis Jun 30, 2026 · 19:32 APS · 2.14 APTOSE BIOSCIENCES INC.

Executive Summary

Aptose Biosciences announced the completion of its plan of arrangement with Hanmi Pharmaceutical Co. Ltd.
HS North America Ltd., a Hanmi subsidiary, acquired all outstanding common shares not already owned by Hanmi for C$2.41 in cash per share.
The transaction represents a 28% premium over the company's 30-day VWAP of C$1.88.
Final court approval and necessary Korean regulatory approvals were secured.
Shares are expected to be delisted from the Toronto Stock Exchange (TSX) around July 3, 2026.
The company has applied to cease reporting status under Canadian securities laws and intends to terminate public reporting requirements in the United States and Canada.
The arrangement was originally announced in November 2025, amended in February 2026, and closed after regulatory delays.

Material Impact

The closing of the acquisition provides a definitive, premium cash exit for minority shareholders, eliminating all public market and going-concern risks associated with the company.
The stock price is expected to converge tightly to the C$2.41 offer price (approximately $1.80 USD at prevailing FX rates, though trading has remained elevated near $2.14-$2.40 due to arbitrage and settlement mechanics).
Operational and clinical development of tuspetinib will continue under Hanmi's private ownership, removing the need for public capital raises or dilutive financing.
The market has already priced in the deal terms and premium over the past several months, limiting any additional upside or downside volatility from this specific announcement.

APS · Price

Company Overview

Aptose Biosciences is a clinical-stage biotechnology company focused on precision oncology therapies.
Its lead asset, tuspetinib, is an oral kinase inhibitor targeting SYK, FLT3, KIT, JAK1/2, and RSK2 kinases.
The company was developing a triplet therapy (tuspetinib + venetoclax + azacitidine) for newly diagnosed AML patients ineligible for induction chemotherapy.
Clinical data from the Phase 1/2 TUSCANY trial demonstrated high response rates (86.2% composite complete response) and robust minimal residual disease (MRD) negativity (86.4% in responders), including in difficult-to-treat genetic subgroups like TP53-mutated and FLT3-unmutated cases.
The company had no commercial revenue and relied entirely on clinical trial funding and advances from Hanmi Pharmaceutical.

More from APTOSE BIOSCIENCES INC.